Navigation Links
China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results
Date:2/28/2011

160;Revenue from processing fees increased by 27.5% to RMB71.7 million ($10.9 million) from the prior year period. This reflects 14,765 new subscriber sign-ups this quarter, a 25.4% increase in new subscriber sign-ups from the prior year period. Revenue from storage fees increased 48.1% year-over-year to RMB18.8 million ($2.8 million), as a result of sustained growth in the accumulated subscriber base.  Revenue from storage fee accounted for 20.8% of the total third quarter revenue, compared to 18.4% in the same period last year. Driven by the strong demand from the Beijing and Guangdong markets, the Company's accumulated subscriber base as of December 31, 2010 reached a new record of 170,189, up 44.7% year-over-year.

GROSS PROFIT. Gross profit in the third quarter increased to RMB69.5 million ($10.5 million), up 33.2% from RMB52.2 million in the same period last year. Gross margin reached a new high by increasing 110 basis points to 76.8% year-over-year, primarily as a result of the rising revenue largely related to rising contribution from storage fees and economies of scale.  

OPERATING INCOME. Operating income for the third quarter reached RMB34.8 million ($5.3 million), up 38.8% from RMB25.1 million, driven by new subscriber numbers, margin expansion and successful cost control measures. Operating income as a percentage of revenues increased slightly to 38.5%, up 210 basis points year-over-year. Depreciation and amortization expense for the third quarter amounted to RMB5.8 million ($0.9 million).

Research and Development expense. Third quarter research and development expense rose to RMB1.9 million ($0.3 million).

Sales and Marketing expense. Sales and marketing expense increased 20.4% to RMB12.5 million ($1.9 million) as the Company continued to expand its marketing resources to cope with rising demand in Beijing and Guangdong. The Company's d
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ShengdaTech to Present at Rodman & Renshaw Annual China Investment Conference in Shanghai
2. China Cord Blood Corporation Forms Zhejiang Subsidiary
3. China Cord Blood Corporation Announces Results of 2010 Annual General Meeting
4. China Cord Blood Corporation to Announce Third Quarter Fiscal 2011 Financial Results
5. China-Biotics to Report Fiscal Year 2011 Third Quarter Financial Results on February 9
6. China-Biotics, Inc. Provides Preliminary FY2011Third Quarter Revenue
7. Reportlinker Adds Industrial Biotechnology China News 1011
8. Reportlinker Adds Financial Health of Biotechnology and Drugs Industry in India and China
9. China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on February 18, 2011
10. China-Biotics, Inc. to Hold 2010 Annual Meeting of Stockholders on March 9, 2011
11. China Cord Blood Corporation Announces Completion of Warrant Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 Dr. Sparano is Professor of ... at the Albert Einstein College of Medicine and Associate ... Medical Center. He is also Associate Director for ... the Einstein Breast Cancer Working Group, a multidisciplinary group ... research. He also serves as Vice Chair of the ...
(Date:5/17/2013)... German . ... eye, you can see which branch a bird is sitting ... through the telephoto lens for high-magnification images requires considerable skill. ... to study proteins, the active biomolecules of cells. , Olga ... Systems Biology, and her colleagues have now come up with ...
(Date:5/17/2013)... PARK, N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability ,     New ... insect pressures , Syngenta unveiled ... celebration today at the company’s RTP Innovation Center. The ... allows company researchers to simulate any agricultural climate and ...
(Date:5/17/2013)... International, Inc. (NASDAQ: YONG ) ("Yongye" or ... crop nutrient products in the People,s Republic ... 16, 2013, the special committee (the "Special Committee") of ... provided a letter (the "Letter") issued by Abax Global ... to Full Alliance International Limited ("Full Alliance"). The Letter, ...
Breaking Biology Technology:Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4
... Without clear leadership and more transparency in federal risk ... a happy accident, rather than a foregone conclusion, says ... Project on Emerging Nanotechnologies (PEN). This sentiment was voiced ... Science & Technology Committees hearing on the National Nanotechnology ...
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), today ... Capital Market listing requirements. On April,16, 2008, the ... that it has regained compliance with Nasdaq,Marketplace Rule ... Company,s,common stock has been equal to or in ...
... Md., April 16 The Board of Managers ... Dr. Danong Chen has,been elected as the new ... previously the President and CEO of Tanox Inc., ... Genentech in 2007.,Previously Dr. Chen was Vice-President of ...
Cached Biology Technology:Limited transparency in federal nanotech research may hamper development 2Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements 2Danong Chen appointed CEO of Theranostics Health 2
(Date:5/16/2013)... Northwestern University scientists have shown a gene involved in ... proper function of the circadian clock. , In ... found the gene, called Ataxin-2, keeps the clock responsible ... the gene, the rhythm of the fruit fly,s sleep-wake ... schedule difficult for the fly. , The discovery ...
(Date:5/16/2013)... May 16, 2013 Integrated Biometrics patented ... a custom thin film transistor camera introduces Sherlock, ... roll image in the smallest and lightest form ... Appendix F Mobile ID FAP 45, Certified scanner ... in size and weight when compared to optical ...
(Date:5/16/2013)... from Canada and around the world are meeting ... Neuroscience Meeting will showcase the latest in research ... reveal clues to understanding the disorders that affect ... and this meeting will showcase the best of ... says Sam David, President of the Canadian Association ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2
... ANAHEIM, CA: Providing healthier food choices for our ... Let,s Move campaign. And a team of researchers ... to help schools serve more fresh vegetables and salad ... Food and Brand Lab, presented the findings of the ...
... NEW YORK, April 27, 2010 The Juvenile ... with Living Cell Technologies (LCT), a New Zealand-based biotechnology ... Phase II clinical trial to study the safety and ... a treatment for type 1 diabetes with significant hypoglycemia ...
... April 27 ViroPharma Incorporated (Nasdaq: VPHM ... multi-dose Phase 2 study to evaluate the safety, and ... Cinryze™ (C1 esterase inhibitor [human)] in 24 adolescents and ... by the U.S. Food and Drug Administration in ...
Cached Biology News:JDRF partners with LCT to test encapsulated cell replacement therapy for the treatment of diabetes 2JDRF partners with LCT to test encapsulated cell replacement therapy for the treatment of diabetes 3ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 2ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 3ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 4ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 5
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... purified from egg white. The extinction coefficient , ... in 10 mM phosphate-buffered saline, pH ... sodium azide and 50% glycerol. Avidin (from egg ... is purified by molecular sieving and ...
... The Zero Blunt TOPO ... Sequencing is designed for ... of blunt-end PCR products. ... 5-minute TOPO Cloning and ...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Biology Products: